Authors:
ZELLNER A
FETELL MR
BRUCE JN
DEVIVO DC
ODRISCOLL KR
Citation: A. Zellner et al., DISPARITY IN EXPRESSION OF PROTEIN-KINASE-C-ALPHA IN HUMAN GLIOMA VERSUS GLIOMA-DERIVED PRIMARY-CELL LINES - THERAPEUTIC IMPLICATIONS, Clinical cancer research, 4(7), 1998, pp. 1797-1802
Authors:
FETELL MR
GROSSMAN SA
FISHER JD
ERLANGER B
ROWINSKY E
STOCKEL J
PIANTADOSI S
Citation: Mr. Fetell et al., PREIRRADIATION PACLITAXEL IN GLIOBLASTOMA-MULTIFORME - EFFICACY, PHARMACOLOGY, AND DRUG-INTERACTIONS, Journal of clinical oncology, 15(9), 1997, pp. 3121-3128
Citation: C. Balmaceda et al., THIOTEPA AND ETOPOSIDE TREATMENT OF RECURRENT MALIGNANT GLIOMAS - PHASE-I STUDY, Cancer chemotherapy and pharmacology, 40(1), 1997, pp. 72-74
Authors:
BALMACEDA C
HESDORFFER C
PAPPADOUPOLOUS K
SIMMONS T
VAHDAT L
GARRET T
ANTMAN K
FETELL MR
Citation: C. Balmaceda et al., FEASIBILITY OF HIGH-DOSE CHEMOTHERAPY (HDC) FOLLOWED BY AUTOLOGOUS ORSTEM-CELL SUPPORT FOR RECURRENT PROGRESSIVE OLIGODENDROGLIOMA(O)/, Neurology, 48(3), 1997, pp. 1004-1004
Authors:
KRAKAUER J
BALMACEDA C
GLUCK JT
POSNER JB
FETELL MR
DALMAU J
Citation: J. Krakauer et al., ANTI-YO-ASSOCIATED PARANEOPLASTIC CEREBELLAR DEGENERATION IN A MAN WITH ADENOCARCINOMA OF UNKNOWN ORIGIN, Neurology, 46(5), 1996, pp. 1486-1487
Citation: C. Balmaceda et al., LONG-TERM SURVIVAL IN MALIGNANT ASTROCYTOMAS REEVALUATED - ARE THEY REALLY OLIGODENDROGLIOMAS, Neurology, 46(2), 1996, pp. 6079-6079
Authors:
BALMACEDA CM
FETELL MR
SELMAN JE
SEPLOWITZ AJ
Citation: Cm. Balmaceda et al., DIABETES-INSIPIDUS AS FIRST MANIFESTATION OF PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA, Neurology, 44(2), 1994, pp. 358-359